SCHEDULE: Armistice Capital Discloses 9.99% Stake in Mainz Biomed

Armistice Capital and Steven Boyd have disclosed a 9.99% beneficial ownership stake in Mainz Biomed N.V., holding 723,092 ordinary shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 723,092 ordinary shares of Mainz Biomed N.V.
• This ownership represents 9.99% of the issuer's outstanding ordinary shares.
• The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC acting as the investment manager and exercising voting and investment power.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported ownership position.
• The reported ownership position is as of June 30, 2025.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, which is neutral in sentiment regarding the company's operational performance or financial health. It simply reports a significant stake by an institutional investor.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a hedge fund in a biotechnology company. Such disclosures are common and reflect investment firms taking positions in publicly traded companies, often without seeking to influence control, as certified in the filing.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed positively as a vote of confidence or simply as a change in the shareholder base.

Key Dates

Keywords

Mainz Biomed, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Equity Stake, Investment Management, Biotech, Healthcare